Literature DB >> 24915254

Revolution to a new standard treatment of diabetic macular edema.

Lee M Jampol1, Neil M Bressler2, Adam R Glassman3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24915254      PMCID： PMC4222042          DOI： 10.1001/jama.2014.2536

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  7 in total

1.  Prevalence of and risk factors for diabetic macular edema in the United States.

Authors:  Rohit Varma; Neil M Bressler; Quan V Doan; Michelle Gleeson; Mark Danese; Julie K Bower; Elizabeth Selvin; Chantal Dolan; Jennifer Fine; Shoshana Colman; Adam Turpcu
Journal:  JAMA Ophthalmol       Date:  2014-11       Impact factor: 7.389

2.  Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States.

Authors:  Neil M Bressler; Rohit Varma; Quan V Doan; Michelle Gleeson; Mark Danese; Julie K Bower; Elizabeth Selvin; Chantal Dolan; Jennifer Fine; Shoshana Colman; Adam Turpcu
Journal:  JAMA Ophthalmol       Date:  2014-02       Impact factor: 7.389

3.  Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.

Authors:  Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; David J Browning; K V Chalam; Matthew Davis; Frederick L Ferris; Adam R Glassman; Raj K Maturi; Cynthia R Stockdale; Trexler M Topping
Journal:  Ophthalmology       Date:  2011-12       Impact factor: 12.079

4.  Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

Authors:  Michael J Elman; Haijing Qin; Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; Frederick L Ferris; Adam R Glassman; Raj K Maturi; Michele Melia
Journal:  Ophthalmology       Date:  2012-09-19       Impact factor: 12.079

5.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

6.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Neil M Bressler; Haijing Qin; Roy W Beck; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

7.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12
  7 in total
  14 in total

1.  Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.

Authors:  Lee M Jampol; Adam R Glassman; Neil M Bressler
Journal:  JAMA Ophthalmol       Date:  2015-09       Impact factor: 7.389

2.  Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema.

Authors:  Sidney A Schechet; Olufemi E Adams; David A Eichenbaum; Seenu M Hariprasad
Journal:  BMJ Open Ophthalmol       Date:  2019-03-29

3.  Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study.

Authors:  Khalil Ghasemi Falavarjani; Sara Golabi; Mehdi Modarres
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-05       Impact factor: 3.117

4.  Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.

Authors:  Gianni Virgili; Mariacristina Parravano; Jennifer R Evans; Iris Gordon; Ersilia Lucenteforte
Journal:  Cochrane Database Syst Rev       Date:  2018-10-16

5.  Short term effect of intravitreal bevacizumab for diabetic macular edema associated with epiretinal membrane.

Authors:  Ashraf Khorasani Maryam; Mohammadi Tafgeh; Motallebi Mahmoud; Anvari Pasha; Sedaghat Ahad; Ghasemi Falavarjani Khalil
Journal:  Rom J Ophthalmol       Date:  2018 Jul-Sep

6.  Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases.

Authors:  Yen-Po Chen; Ai-Ling Wu; Chih-Chun Chuang; San-Ni Chen
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

7.  Anxiety and depression in patients who receive anti-VEGF treatment and the usability and feasibility of e-mental health support: the E-PsEYE pilot study.

Authors:  Hilde Pa van der Aa; Ger Hmb van Rens; Frank D Verbraak; Machteld Bosscha; Hannie C Comijs; Ruth Ma van Nispen
Journal:  Ophthalmic Physiol Opt       Date:  2021-05-29       Impact factor: 3.117

Review 8.  Do Genomic Factors Play a Role in Diabetic Retinopathy?

Authors:  Andrea P Cabrera; Finny Monickaraj; Sampathkumar Rangasamy; Sam Hobbs; Paul McGuire; Arup Das
Journal:  J Clin Med       Date:  2020-01-14       Impact factor: 4.241

9.  Association between Hyperreflective Foci on Spectral-Domain Optical Coherence Tomography and Early Recurrence of Diabetic Macular Edema after Intravitreal Dexamethasone Implantation.

Authors:  Kyung Tae Kim; Dong Yoon Kim; Ju Byung Chae
Journal:  J Ophthalmol       Date:  2019-11-19       Impact factor: 1.909

10.  A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.

Authors:  Weishai Liu; Yanjie Li; Rongxia Cao; Zichao Bai; Weiqin Liu
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.